11-03-2026, 22:10

Io Therapeutics, Inc. announces publication of studies on the company’s RXR agonist compound IRX4204 for breast cancer prevention

Notified -
Globe Newswire11-03-2026, 22:10
6-12-2025, 20:05

Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human mul

Notified -
Globe Newswire6-12-2025, 20:05
13-12-2024, 00:37

FAAM-EUROBAT 2024 Concludes with Groundbreaking Advances in Food Allergy and Anaphylaxis Research

Notified -
Globe Newswire13-12-2024, 00:37